Kicking the habit: Smoking rate among Americans hits a historic low

U.S. adult cigarette smoking fell to 9.8% in 2024 from 10.8% in 2023 — the lowest level on record — while 18.8% of adults used at least one tobacco product in 2024. E-cigarette use is rising, concentrated among younger adults (13% regular use vs 1.1% for 65+ per United Health Foundation) and 1.63 million middle/high school students used e-cigarettes in 2024, offsetting cigarette progress. Public-health groups call for rebuilding CDC tobacco prevention efforts and stronger FDA oversight; smoking still contributes to ~480,000 deaths annually and ~20% of U.S. cancers.

Analysis

The secular move away from combustibles forces tobacco firms to reprice their business models: legacy cigarette volumes are becoming a lower-growth cash engine while margin expansion opportunities sit with proprietary non-combustible formats that sell consumables (pods, pouches, refills). Companies that have both proprietary hardware and closed consumable ecosystems can convert unit share losses into recurring revenue growth, improving FCF visibility even as headline volumes decline.

Regulatory action is the dominant tail risk and the most likely near-term catalyst; targeted measures (flavor bans, nicotine caps, tighter marketing rules) can compress adoption curves for certain reduced‑risk products within 6–18 months, while broader regulatory recalibrations or litigation play out over multiple years. Market reactions to single high‑profile youth cases or federal rule changes could move sector multiples sharply and non-linearly.

Retail and supply‑chain second-order effects are underappreciated: convenience-store foot traffic and impulse purchase economics will shift, pressuring low-margin incumbents while increasing value for suppliers of high-margin nicotine consumables and packaging. At the same time, consolidation in flavorings, pod manufacturing, and battery supply could create fast followers with pricing power, favouring multi‑category vendors over niche pure‑plays.

The consensus misses nicotine’s stickiness — even if cigarette use falls, addicted cohorts sustain demand for alternatives, allowing leaders to re-monetize nicotine via new form-factors. That creates a bifurcated opportunity set: high-beta growth optionality in companies executing a credible shift to consumable ecosystems, versus value traps among firms tethered to combustible economics or exposed to US regulatory/legal headlines.

Key Decisions for Investors

• Pair trade (12–18 months): Long BTI (British American Tobacco) 1x / Short MO (Altria) 1x. Rationale: BTI has broader product set in pouches/heated formats outside the pure-US combustible franchise; MO retains concentrated US combustible exposure and litigation/regulatory sensitivity. Target: 20–35% relative upside on the pair if regulators remain incremental; risk: 25–30% adverse move if a major US regulatory shock or unexpected product recall occurs. Use 6–12% notional sizing with 1:1 share weighting and monitor FDA/legislative headlines weekly.
• Option-structured long (12–24 months): Buy PM (Philip Morris International) 12–18 month call spread (long lower strike, short higher strike) sized to 3–5% portfolio. Rationale: capture convexity from successful RRP adoption while capping premium outlay; expected payoff if international adoption and pricing on proprietary heated products accelerate. Risk: reduced if global regulation tightens; keep downside capped to the premium and hedge with short-dated puts if newsflow turns adverse.
• Defensive small position (6–12 months): Buy PFE (Pfizer) or other large pharma exposure (3–4% position) as a hedge for increased demand for cessation pharmacotherapies if public health campaigns intensify. Rationale: regulatory crackdowns on youth vaping drive policy support and treatment uptake in the near term. Reward: modest upside from steady product sales and defensive downside during regulatory volatility; risk: clinical/market substitution reduces uplift—keep position small and review after major policy announcements.